Plagued by reports of dangerous side effects, Johnson & Johnson says it will spend $100 million to retest its heart failure drug Natrecor. Its subsidiary, Scios, says it will test 7,000 patients in the U.S., Canada and Europe. No lead researcher has been selected for the study. Specialists have voiced their concern that the drug has been used in an outpatient setting instead of being restricted to the hospital.
- read this New York Times report